Individualised computerised cognitive training for community-dwelling people with mild cognitive impairment: study protocol of a completely virtual, randomised, controlled trial.
Community-dwelling
Computerised cognitive training
Mild cognitive impairment
Non-pharmacological intervention
Randomised controlled trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
05 May 2022
05 May 2022
Historique:
received:
13
04
2021
accepted:
06
03
2022
entrez:
5
5
2022
pubmed:
6
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
People with mild cognitive impairment (MCI) are at increased risk of converting to dementia. Cognitive training can improve the cognitive abilities of people with MCI. Computerised cognitive training (CCT) offers several advantages over traditional paper-and-pencil cognitive training and has the potential to be more individualised by matching task difficulty with individual performance. Recent systematic reviews have reported promising effects of CCT on improving the cognitive capacities of people with MCI. However, the quality of existing studies has been limited, and it is still unclear whether CCT can influence the progression to dementia. We developed an 'individualised' CCT (MAKSCog) specialised for people with MCI that automatically matches task difficulty with individual performance and an active control training ('basic' CCT). The aims of the present study are (a) to evaluate MAKSCog and (b) to investigate whether it can be applied to maintain the cognitive abilities of people with MCI. The present study investigates the effects of CCT on cognition in a randomised controlled intervention study in Germany. Participants are community-dwelling people with a psychometric diagnosis of MCI based on the Montreal Cognitive Assessment (MoCA) and Mini-Mental Status Test (MMSE). Screening and baseline testing are conducted via a videoconferencing assessment and telephone. Participants are randomly allocated. The treatment phase is 6 months with an open phase in which participants can freely decide to continue to use the CCTs. Additionally, both CCTs contain a monthly computerised cognitive assessment that measures different cognitive abilities: information processing speed, memory span, short term memory, and logical reasoning. This is the first study to investigate the effect of MAKSCog, an individualised CCT, specifically developed for people with different subtypes of MCI. A methodological strength is the double-blind, randomised, controlled design and the use of basic CCT as an active control group. The study is conducted entirely virtually with valid telehealth assessments for cognitive function. Methodological limitations might include a restriction to participants who feel comfortable with the use of technology and who own a computer, laptop, or tablet. ISRCTN ISRCTN14437015 . Prospectively registered on 27 February 2020.
Sections du résumé
BACKGROUND
BACKGROUND
People with mild cognitive impairment (MCI) are at increased risk of converting to dementia. Cognitive training can improve the cognitive abilities of people with MCI. Computerised cognitive training (CCT) offers several advantages over traditional paper-and-pencil cognitive training and has the potential to be more individualised by matching task difficulty with individual performance. Recent systematic reviews have reported promising effects of CCT on improving the cognitive capacities of people with MCI. However, the quality of existing studies has been limited, and it is still unclear whether CCT can influence the progression to dementia. We developed an 'individualised' CCT (MAKSCog) specialised for people with MCI that automatically matches task difficulty with individual performance and an active control training ('basic' CCT). The aims of the present study are (a) to evaluate MAKSCog and (b) to investigate whether it can be applied to maintain the cognitive abilities of people with MCI.
METHODS
METHODS
The present study investigates the effects of CCT on cognition in a randomised controlled intervention study in Germany. Participants are community-dwelling people with a psychometric diagnosis of MCI based on the Montreal Cognitive Assessment (MoCA) and Mini-Mental Status Test (MMSE). Screening and baseline testing are conducted via a videoconferencing assessment and telephone. Participants are randomly allocated. The treatment phase is 6 months with an open phase in which participants can freely decide to continue to use the CCTs. Additionally, both CCTs contain a monthly computerised cognitive assessment that measures different cognitive abilities: information processing speed, memory span, short term memory, and logical reasoning.
DISCUSSION
CONCLUSIONS
This is the first study to investigate the effect of MAKSCog, an individualised CCT, specifically developed for people with different subtypes of MCI. A methodological strength is the double-blind, randomised, controlled design and the use of basic CCT as an active control group. The study is conducted entirely virtually with valid telehealth assessments for cognitive function. Methodological limitations might include a restriction to participants who feel comfortable with the use of technology and who own a computer, laptop, or tablet.
TRIAL REGISTRATION
BACKGROUND
ISRCTN ISRCTN14437015 . Prospectively registered on 27 February 2020.
Identifiants
pubmed: 35513855
doi: 10.1186/s13063-022-06152-9
pii: 10.1186/s13063-022-06152-9
pmc: PMC9069424
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
371Subventions
Organisme : Reinhard Frank-Stiftung
ID : none given
Informations de copyright
© 2022. The Author(s).
Références
Mem Cognit. 1982 Jul;10(4):389-95
pubmed: 7132716
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Int Psychogeriatr. 2012 Mar;24(3):391-6
pubmed: 22014176
J Telemed Telecare. 2019 May;25(4):197-203
pubmed: 29320916
Cochrane Database Syst Rev. 2016 Jan 13;(1):CD011145
pubmed: 26760674
Dtsch Arztebl Int. 2017 Dec 1;114(48):815-821
pubmed: 29249224
Int J Geriatr Psychiatry. 2020 Jan;35(1):12-28
pubmed: 31617247
JAMA Intern Med. 2015 Sep;175(9):1450-8
pubmed: 26052687
J Alzheimers Dis. 2017;60(3):877-887
pubmed: 28922157
PLoS One. 2012;7(7):e40588
pubmed: 22792378
Clin Neuropsychol. 2020 Oct - Nov;34(7-8):1411-1452
pubmed: 32519594
BMC Med. 2011 Dec 01;9:129
pubmed: 22133165
Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):37-43
pubmed: 22193353
J Int Neuropsychol Soc. 2012 Mar;18(2):242-50
pubmed: 22115097
Cochrane Database Syst Rev. 2015 Mar 05;(3):CD010783
pubmed: 25740785
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Neurology. 2018 Jan 16;90(3):126-135
pubmed: 29282327
Curr Geriatr Rep. 2020 Jun;9(2):72-81
pubmed: 32509504
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Am J Psychiatry. 2017 Apr 1;174(4):329-340
pubmed: 27838936
Front Psychol. 2020 Apr 09;11:648
pubmed: 32373018
BMC Geriatr. 2018 Sep 15;18(1):213
pubmed: 30219036
BMJ Open. 2019 Aug 18;9(8):e027062
pubmed: 31427316
J Nutr Health Aging. 2010 Jan;14(1):31-5
pubmed: 20082051
Br J Gen Pract. 2007 Aug;57(541):650-2
pubmed: 17688760
Cortex. 2008 Oct;44(9):1248-55
pubmed: 18761138
J Neurol. 2021 May;268(5):1680-1688
pubmed: 31650255
Curr Psychiatry Rep. 2016 Sep;18(9):85
pubmed: 27481112
Neuropsychol Rev. 2016 Sep;26(3):225-251
pubmed: 27632385
Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):345-59
pubmed: 20633738
Int Psychogeriatr. 2012 Nov;24(11):1749-55
pubmed: 22687278
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Psychol Rev. 1996 Jul;103(3):403-28
pubmed: 8759042
Acta Neurol Scand Suppl. 2003;179:42-6
pubmed: 12603250
J Am Geriatr Soc. 1992 Sep;40(9):922-35
pubmed: 1512391
Cochrane Database Syst Rev. 2019 Mar 13;3:CD012279
pubmed: 30864747
BMC Neurol. 2012 Dec 05;12:151
pubmed: 23217188
Arch Clin Neuropsychol. 2016 Aug;31(5):420-5
pubmed: 27246957
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Am J Geriatr Psychiatry. 2015 Apr;23(4):335-359
pubmed: 24998488
J Alzheimers Dis. 2016;51(2):619-29
pubmed: 26890758